• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line).
  

PubMed=2846161
Hospers G.A.P., Mulder N.H., de Jong B., de Leij L.F.M.H., Uges D.R.A., Fichtinger-Schepman A.M.J., Scheper R.J., de Vries E.G.E.
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Cancer Res. 48:6803-6807(1988)

PubMed=2163989; DOI=10.1002/ijc.2910460125
Hospers G.A.P., Meijer C., de Leij L.F.M.H., Uges D.R.A., Mulder N.H., de Vries E.G.E.
A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.
Int. J. Cancer 46:138-144(1990)

PubMed=1657425; DOI=10.1007/BF00685823
de Jong S., Zijlstra J.G., Mulder N.H., de Vries E.G.E.
Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
Cancer Chemother. Pharmacol. 28:461-464(1991)

PubMed=12093475; DOI=10.1016/S0006-2952(02)00983-8
Fokkema E., Groen H.J.M., Helder M.N., de Vries E.G.E., Meijer C.
JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Biochem. Pharmacol. 63:1989-1996(2002)

PubMed=20615970; DOI=10.1073/pnas.1008132107; PMCID=PMC2919980
Voortman J., Lee J.-H., Killian J.K., Suuriniemi M., Wang Y.-H., Lucchi M., Smith W.I. Jr., Meltzer P.S., Wang Y.-S., Giaccone G.
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
Proc. Natl. Acad. Sci. U.S.A. 107:13040-13045(2010)